Skip to content
ChickenStockChickenStock
ResearchALNY
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals (ALNY) stock

NASDAQ

$156.49-2.03%(-3.24)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

8.52x

P/B

5.82x

P/S

4.72x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 16.7% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Oct 29, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

6 SEC filings
  • Greenstreet YvonneChief Executive Officer · Nov 13, 2026Gift11,000 shares · $0
    Avg. price $084,802 shares held after
  • Sigal Charles ElliottDirector · Nov 10, 2026Open-market purchase1,600 shares · $244K
    Avg. price $152.253,600 shares held after
  • PYOTT DAVID E IDirector · Nov 10, 2026Option exercise3,780 shares · $272K
    Avg. price $71.995,362 shares held after
  • SCHULMAN AMY WDirector · Nov 9, 2026Open-market purchase1,910 shares · $300K
    Avg. price $156.8225,959 shares held after
  • SUPRAN BRYANEVP, CLO and Secretary · Oct 2, 2026Open-market sale1,758 shares · $399K
    Avg. price $226.8812,807 shares held after
  • Greenstreet YvonneChief Executive Officer · Sep 19, 2026Grant or award107 shares · $0
    Avg. price $095,802 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Alnylam Pharmaceuticals (ALNY) stock information

NASDAQ

Alnylam Pharmaceuticals (ALNY) is listed on NASDAQ. Its market capitalization is about $21B. On trailing-twelve-month earnings the P/E ratio is 8.52, and the P/B ratio is 5.82. Return on equity is 68.3%. These figures are computed in-house from official filings and are reference information only.

Alnylam Pharmaceuticals — frequently asked questions

What is the P/E ratio of Alnylam Pharmaceuticals (ALNY)?
On a trailing-twelve-month basis, ALNY trades at a P/E ratio of 8.52. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Alnylam Pharmaceuticals?
ALNY has a market capitalization of about $21B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.